New version ReCell launched in UK and Europe

THE ROADHOUSE PHARMACY: Regenerative medicine company Avita Medical (ASX: AVH) has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration.

The company claims this greatly improves the commercial and practical benefits to clinicians.

The new version of ReCell has been cleared for use and is starting to be sold in the United Kingdom and Europe.

Avita Medical indicated it is also in the process of submitting an application for review to the Therapeutic Goods Administration (TGA) in Australia, where the product must currently be refrigerated.

The company said the regulatory approval and commercial launch of the non‐refrigerated ReCell is part of its ongoing commercialisation strategy for its ReCell ‘Spray‐on Skin’ technology, which includes improvements in ease‐of‐use to enhance the product’s value proposition to the clinical market.

Avita Medical believes the elimination of the inconvenience associated with temperature‐controlled product would be valuable in generating ReCell sales.

“Until now, ReCell has required refrigeration, which often meant it was not immediately on hand in the operating theatre,” Avita Medical interim chief executive officer Tim Rooney said in the company’s announcement to the Australian Securities Exchange.

“The fact that this product can be stored on the shelf until use is a valuable element in providing a more convenient and attractive product, particularly in situations where time is of crucial importance.”

“Our aim is to develop, trial, register and sell exceptional tools and products that provide benefits to patients and integrate well into clinical practice.

“I believe this is a positive step in our marketing strategy to increase ReCell sales.”

Website: www.avitamedical.com